Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marizyme Inc
(OP:
MRZM
)
0.0429
-0.0071 (-14.20%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,845
Open
0.0429
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0500
Today's Range
0.0429 - 0.0429
52wk Range
0.0313 - 0.4050
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft
May 06, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft
May 06, 2024
JUPITER, FL - (NewMediaWire) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft® will no longer require refrigerated storage and will be able to be...
Via
TheNewswire.com
Topics
Economy
Exposures
Product Safety
Supply Chain
Performance
YTD
-65.71%
-65.71%
1 Month
+30.00%
+30.00%
3 Month
-53.87%
-53.87%
6 Month
-57.10%
-57.10%
1 Year
-71.42%
-71.42%
More News
Read More
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
April 16, 2024
Via
NewMediaWire
Exposures
Product Safety
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
April 16, 2024
Via
TheNewswire.com
Exposures
Product Safety
Marizyme CEO Delivers Business Update
October 23, 2023
Via
NewMediaWire
Exposures
Product Safety
InvestmentPitch Media Video Features Marizyme's CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device
October 13, 2023
Via
ACCESSWIRE
The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News
October 06, 2023
Via
ACCESSWIRE
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft
October 06, 2023
Via
NewMediaWire
Exposures
Product Safety
Marizyme (OTCQB: MRZM) Announces IP Developments for DuraGraft and Its Pipeline Products
May 10, 2023
Via
Spotlight Growth
Topics
Intellectual Property
Exposures
Intellectual Property
Marizyme Announces IP Developments for DuraGraft and Its Pipeline Products
May 10, 2023
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Marizyme (OTCQB: MRZM) CEO Delivers Business Update
May 03, 2023
Via
Spotlight Growth
Exposures
Product Safety
Marizyme CEO Delivers Business Update
May 03, 2023
Via
NewMediaWire
Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office
January 05, 2022
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing
December 23, 2021
Via
NewMediaWire
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
December 03, 2021
Via
NewMediaWire
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
December 03, 2021
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
November 16, 2021
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.